Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Buparlisib + Elgemtumab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Buparlisib | BKM-120|BKM120 | PI3K Inhibitor (Pan) 40 | Buparlisib (BKM120) specifically inhibits class I PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway in an ATP-competitive manner, and may result in apoptotic activity and inhibition of cell proliferation (PMID: 22188813). | |
Elgemtumab | LJM716|LJM-716 | HER3 (ERBB3) Antibody 23 | Elgemtumab (LJM716) is a monoclonal antibody that targets ErbB3 (Her3) and prevents its transition into an active conformation, resulting in inhibition of ligand-dependent and ligand-independent downstream signaling and decreased tumor cell proliferation (PMID: 23928993, PMID: 27942917). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ERBB3 over exp PIK3CA H1047R | breast cancer | sensitive | Buparlisib + Elgemtumab | Preclinical - Cell line xenograft | Actionable | In a preclinical study, a breast cancer cell line xenograft model harboring ERBB3 (HER3) over expression and PIK3CA H1047R in brain metastases was sensitive to the combined treatment of Buparlisib (BKM120) and LJM716, demonstrating delayed tumor growth and better survival when compared to either treatment alone (PMID: 28539475). | 28539475 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|